论文部分内容阅读
目的:探索达芬奇机器人治疗前列腺癌合并冠心病患者的安全性和有效性。方法:回顾性分析我院2012年7月~2017年2月采用达芬奇机器人辅助腹腔镜手术治疗前列腺癌伴发冠心病患者的临床资料。结果:我院应用达芬奇机器人手术治疗前列腺癌伴发冠心病的患者共31例,平均年龄68(58~78)岁。术前总前列腺特异性抗原(tPSA)为17.0(1.81~66.0)ng/ml;手术全部成功,术前抗凝药物停服时间为8.8(6~21)d;手术时机器人外科手术系统准备时间为21(13~40)min;平均手术时间139(90~230)min,平均出血量161(20~450)ml。所有患者的手术过程顺利,无中转开放手术、无手术并发症。住院时间为12(7~25)d,导尿管保留时间为15(7~23)d。术后6周复查PSA为0.07(0~0.5)ng/ml。结论:机器人手术在伴发冠心病的前列腺癌患者中的应用是安全有效的。
Objective: To explore the safety and efficacy of Da Vinci robot in treating patients with prostate cancer complicated with coronary heart disease. Methods: A retrospective analysis of our hospital from July 2012 to February 2017 using da Vinci robot assisted laparoscopic surgery in patients with prostate cancer associated with coronary heart disease clinical data. Results: 31 cases of prostate cancer patients with coronary heart disease were treated by Da Vinci robot in our hospital, with an average age of 68 (58-78) years. The total preoperative total prostate specific antigen (tPSA) was 17.0 (1.81 ~ 66.0) ng / ml. The operation was completed successfully. The preoperative anticoagulant duration was 8.8 (6 ~ 21) d. The robot surgical system preparation time The mean operative time was 139 (90-230) min and the mean amount of bleeding was 161 (20-450) ml. All patients underwent a successful surgical procedure without open surgery and no complications. Hospitalization time was 12 (7 ~ 25) d, catheter retention time was 15 (7 ~ 23) d. PSA was 0.07 (0-0.5) ng / ml at 6 weeks postoperatively. Conclusion: The use of robotic surgery in patients with prostate cancer with coronary heart disease is safe and effective.